n e w s r e l e a s e Exhibit 99.1 Humana Inc. 500 West Main Street P.O. Box 1438 Louisville, KY 40202 http://www.humana.com

FOR MORE INFORMATION CONTACT:

Lisa Stoner Humana Investor Relations (502) 580-2652 e-mail: LStamper@humana.com

Mark Taylor

Humana Corporate Communications

(317) 753-0345

e-mail: MTaylor108@humana.com

Humana Reports Third Quarter 2023 Financial Results;

AffirmsFull Year 2023 Adjusted EPS Guidance

•Reports 3Q23 earnings per share (EPS) of $6.71on a GAAP basis,Adjusted EPS of $7.78; reports YTD 2023 EPS of$24.26 on a GAAP basis, $26.10 on an Adjusted basis

◦Reflects outperformance in the company's Medicaid and Primary Care businesses along with a continued focus on driving sustainable operating efficiencies, offset by modestly higher than anticipated utilization in the Medicare Advantage business

•Revises FY 2023 EPS guidance to 'at least $26.31' on a GAAP basis, affirms FY 2023 Adjusted EPS of 'at least $28.25'

•Raises 2023 individual Medicare Advantage membership growth by 35,000 to 'approximately 860,000', or 19percent growth over FY 2022 ending membership, meaningfully higher than industry growth

•Anticipates 2024 individual Medicare Advantage membership growth at or above industry growth level

•Achieves 94 percent of the company's Medicare Advantage members currently enrolled in 4-star and above contracts for 2024, an industry-leader among its publicly traded peers for the sixth consecutive year; 61 percent of members in 4.5 and 5-star contracts

LOUISVILLE, KY (November 1, 2023) – Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended September 30, 2023 (3Q23) versus the quarter ended September 30, 2022 (3Q22) and for the nine months ended September 30, 2023 (YTD 2023) versus the nine months ended September 30, 2022 (YTD 2022) as noted in the tables below.

1

Consolidated income before income taxes and equity in net earnings (pretax results) In millions	3Q23 (a)	3Q22 (a)	YTD 2023 (a)	YTD 2022 (a)
Generally Accepted Accounting Principles (GAAP)	$1,098	$1,297	$3,974	$3,639
Amortization associated with identifiable intangibles	17	25	51	61
Put/call valuation adjustments associated with company's non-consolidating minority interest investments	35	13	141	(16)
Transaction and integration costs	—	17	(47)	70
Change in fair market value of publicly-traded equity securities	—	(51)	(1)	119
Impact of exit of employer group commercial medical products business	51	70	15	48
Accrued charge related to certain anticipated litigation expenses	15	—	105	—
Value creation initiatives	52	82	52	285
Gain on sale of Gentiva (formerly Kindred) Hospice	—	(240)	—	(240)
Adjusted (non-GAAP)	$1,268	$1,213	$4,290	$3,966

Diluted earnings per share (EPS)	3Q23 (a)	3Q22 (b)	YTD 2023 (a)	YTD 2022 (a)
GAAP	$6.71	$9.39	$24.26	$22.16
Amortization associated with identifiable intangibles	0.14	0.20	0.41	0.48
Put/call valuation adjustments associated with company's non-consolidating minority interest investments	0.28	0.10	1.13	(0.13)
Transaction and integration costs	—	0.13	(0.38)	0.55
Change in fair market value of publicly-traded equity securities	—	(0.40)	(0.01)	0.94
Impact of exit of employer group commercial medical products business	0.42	0.55	0.12	0.37
Accrued charge related to certain anticipated litigation expenses	0.12	—	0.84	—
Value creation initiatives	0.42	0.65	0.42	2.24
Net gain on the sale of Gentiva (formerly Kindred) Hospice	—	(1.89)	—	(1.89)
Cumulative net tax impact of non-GAAP adjustments	(0.31)	(1.42)	(0.69)	(0.84)
Adjusted (non-GAAP)	$7.78	$7.31	$26.10	$23.88

For comparative purposes, the 3Q22 and YTD 2022 reconciliations noted in the preceding tables have been recast to exclude the impact of the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023. Additionally, 3Q22 and YTD 2022 per share impacts have been recast to disclose the pretax per share impact of each adjustment, followed by a cumulative net tax impact. Refer to the "Footnotes" section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.

“Our third quarter results reinforce Humana’s commitment to delivering strong earnings growth, especially considering the 19 percent increase in our individual Medicare Advantage membership which significantly outpaces the industry growth rate," said Bruce D. Broussard, Humana’s President and Chief Executive Officer. “Our results can be partially attributed to our team’s continued focus on advancing our CenterWell capabilities, driving durable productivity, and prioritizing quality. Our industry-leading Star Ratings for the sixth consecutive year, our strong Net Promoter Scores, and our numerous awards for customer experience are a testament to our commitment to the health, well-being, and satisfaction of our customers and to our being a trusted brand within the broker community. Our fundamentals are strong and we remain committed to our 2025 Adjusted EPS target of $37, reflecting a 14 percent compound annual growth rate from 2022 to 2025.”

Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-comparisons.

In addition, a summary of key consolidated and segment statistics comparing 3Q23 to 3Q22 and YTD 2023 to YTD 2022 follows.

2

Prior period segment financial information has been recast to conform to Humana's recently revised segment presentation, as disclosed as part of the company's fourth quarter 2022 earnings release dated February 1, 2023. Additionally, 3Q22 and YTD 2022 Adjusted metrics have also been recast to exclude the impact of the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.

Humana Inc. Summary of Results ($ in millions, except per share amounts)	3Q23 (a)	3Q22 (a)	YTD 2023 (a)	YTD 2022 (a)
CONSOLIDATED
Revenues	$26,423	$22,799	$79,912	$70,431
Revenues - Adjusted (non-GAAP)	$25,526	$21,600	$76,911	$67,001
Pretax results	$1,098	$1,297	$3,974	$3,639
Pretax results - Adjusted (non-GAAP)	$1,268	$1,213	$4,290	$3,966
EPS	$6.71	$9.39	$24.26	$22.16
EPS - Adjusted (non-GAAP)	$7.78	$7.31	$26.10	$23.88
Benefits expense ratio	86.6%	85.6%	86.2%	86.0%
Benefits expense ratio - Adjusted (non-GAAP)	86.4%	85.3%	86.1%	85.9%
Operating cost ratio	12.5%	13.5%	11.8%	13.0%
Operating cost ratio - Adjusted (non-GAAP)	12.0%	12.8%	11.3%	12.2%
Operating cash flows			$11,115	$9,714
Operating cash flows - Adjusted (non-GAAP) (b)			$4,042	$3,936
Parent company cash and short term investments			$518	$1,183
Debt-to-total capitalization			41.1%	39.4%
Days in Claims Payable (DCP)	43.1	46.2
INSURANCE SEGMENT
Revenues	$25,511	$21,743	$77,289	$67,242
Revenues - Adjusted (non-GAAP)	$24,614	$20,595	$74,289	$63,693
Benefits expense ratio	87.6%	85.8%	86.8%	86.3%
Benefits expense ratio - Adjusted (non-GAAP)	87.4%	85.5%	86.8%	86.2%
Operating cost ratio	10.4%	10.6%	9.9%	9.7%
Operating cost ratio - Adjusted (non-GAAP)	9.9%	10.1%	9.4%	9.2%
Income from operations	$722	$873	$3,080	$2,976
Income from operations - Adjusted (non-GAAP)	$794	$955	$3,217	$3,046
CENTERWELL SEGMENT
Revenues	$4,660	$4,274	$13,695	$13,166
Operating cost ratio	90.3%	92.0%	91.5%	91.2%
Income from operations	$400	$300	$1,017	$1,028
Income from operations - Adjusted (non-GAAP) (c)	$453	$345	$1,169	$1,164

Refer to the "Footnotes" section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.

3

2023 Earnings Guidance

Humana revised its GAAP EPS guidance for the year ending December 31, 2023 (FY 2023) to 'at least $26.31' from 'at least $26.91', while affirmingits Adjusted EPS guidance of 'at least $28.25'. The Adjusted EPS guidance reflects a $0.25 increase from the initial guidance of 'at least $28.00', issued as part of the company's fourth quarter 2022 earnings release.

Diluted earnings per common share	FY 2023  Guidance (d)	FY 2022
GAAP	at least $26.31	$22.08
Amortization of identifiable intangibles	0.53	0.64
Put/call valuation adjustments associated with company's non-consolidating minority interest investments	1.13	0.53
Transaction and integration costs	(0.38)	0.83
Change in fair market value of publicly-traded equity securities	(0.01)	0.97
Impact of exit of employer group commercial medical products business	0.13	0.84
Accrued charge related to certain anticipated litigation expenses	0.84	—
Value creation initiatives	0.42	3.72
Net gain on the sale of Gentiva (formerly Kindred) Hospice	—	(1.86)
Cumulative net tax impact of non-GAAP adjustments	(0.72)	(1.87)
Adjusted (non-GAAP) – FY 2023 projected; FY 2022 reported	at least $28.25	$25.88

For comparative purposes, the FY 2022 reconciliation noted in the preceding table has been recast to exclude the impact of the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023. Refer to the "Footnotes" section included herein for further explanation on disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.

CMS Star Ratings

As previously disclosed, in October 2023, the Centers for Medicare and Medicaid Services (CMS) published its updated Medicare Star Ratings for bonus year 2025 (plan year 2024). Humana has nearly 5.5 million members, or 94 percent of its existing Medicare Advantage membership, currently enrolled in plans rated 4-stars or above, with plans available in all 50 states and Puerto Rico. Four of Humana's contracts received a 5-star rating, covering approximately 790,000 members nationwide and more than doubling the number of members in 5-star plans in 2023. This contributes to the nearly 3.6 million, or 61 percent, of the company's Medicare Advantage members in plans rated 4.5 stars or higher.

About 97.5 percent of retirees in Humana's group Medicare Advantage rated plans remain in 4-star or above contracts for 2024.

Detailed Press Release

Humana’s full earnings press release, including the statistical pages, has been posted to the company’s Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company’s website).

Conference Call

Humana will host a conference call at 9:00 a.m. Eastern time today to discuss its financial results for the quarter and the company’s expectations for future earnings.

To participate via phone, please register in advance at this link - https://register.vevent.com/register/BId758ed43d68741ac92865ada642803d4 .

4

Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID that can be used to access the call. A webcast of the 3Q23 earnings call may also be accessed via Humana’s Investor Relations page at humana.com. The company suggests participants for both the conference call and those listening via the web dial in or sign on at least 15 minutes in advance of the call.

For those unable to participate in the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at humana.com, approximately two hours following the live webcast.

Footnotes

The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company’s core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent and uniform indicators of the company’s core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.

(a) For the periods covered in this earnings press release, the following items are excluded from the non-GAAP financial

measures described above, as applicable:

•Amortization associated with identifiable intangibles - Since amortization varies based on the size and timing of acquisition activity, management believes this exclusion provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments income from operations. The table below discloses respective period amortization expense for each segment.

	3Q23	3Q22	YTD 2023	YTD 2022
Insurance segment	$6	$12	$17	$22
CenterWell segment	$11	$13	$34	$39

•Put/call valuation adjustments associated with company’s non-consolidating minority interest investments - These amounts are the result of fair value measurements associated with our Primary Care Organization strategic partnership and are unrelated to the company's core business operations. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS.

•Transaction and integration costs - The transaction and integration costs primarily relate to the acquisition of Kindred at Home in 2021 and the subsequent divestiture of Gentiva (formerly Kindred) Hospice in 2022. For YTD 2023, 3Q22, and YTD 2022, GAAP measures affected include consolidated pretax results, EPS, and the consolidated operating cost ratio.

•Impact of exit of employer group commercial medical products business - Prior period segment financial information has been recast to exclude the impact of the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, consolidated revenues, consolidated benefit expense ratio, consolidated operating cost ratio, Insurance segment revenues, Insurance segment benefit expense ratio, Insurance segment operating cost ratio, and Insurance segment income from operations.

•Accrued charge related to certain anticipated litigation expenses - This charge relates to certain anticipated expenses the company has accrued in connection with a legal matter. For 3Q23 and YTD 2023, GAAP measures affected include consolidated pretax results, EPS, the consolidated and Insurance segment operating cost ratios, and Insurance segment income from operations.

•Change in fair value of publicly-traded equity securities - These gains and losses are a result of market and economic conditions that are unrelated to the company's core business operations. For YTD 2023, 3Q22, and YTD 2022, GAAP measures affected include consolidated pretax results and EPS.

•Value creation initiatives - These charges relate to the company's ongoing initiative to drive additional value for the enterprise through cost saving, productivity initiatives, and value creation from previous investments, and primarily consist

5

of asset impairment and severance charges. For all periods shown in this earnings release, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio.

•Gain on sale of Gentiva (formerly Kindred) Hospice - This gain related to the sale of the company's 60 percent ownership of Gentiva Hospice. For 3Q22 and YTD 3Q22, GAAP measures affected include consolidated pretax results and EPS.

•Cumulative net tax impact of non-GAAP adjustments - This adjustment represents the cumulative net impact of the corresponding tax benefit or expense related to the aforementioned items excluded from the applicable GAAP measures. For all periods presented in this earnings release, EPS is the sole GAAP measure affected.

In addition to the reconciliations shown on page 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release:

Revenues

Revenues - CONSOLIDATED (in millions)	3Q23	3Q22	YTD 2023	YTD 2022
GAAP	$26,423	$22,799	$79,912	$70,431
Change in fair market value of publicly-traded equity securities	—	(51)	(1)	119
Impact of exit of employer group commercial medical products business	(897)	(1,148)	(3,000)	(3,549)
Adjusted (non-GAAP)	$25,526	$21,600	$76,911	$67,001

Revenues - INSURANCE SEGMENT (in millions)	3Q23	3Q22	YTD 2023	YTD 2022
GAAP	$25,511	$21,743	$77,289	$67,242
Impact of exit of employer group commercial medical products business	(897)	(1,148)	(3,000)	(3,549)
Adjusted (non-GAAP)	$24,614	$20,595	$74,289	$63,693

Benefit Expense Ratio

Benefit expense ratio - CONSOLIDATED	3Q23		3Q22		YTD 2023		YTD 2022
GAAP	86.6	%	85.6	%	86.2	%	86.0	%
Impact of exit of employer group commercial medical products business	(0.2)	%	(0.3)	%	(0.1)	%	(0.1)	%
Adjusted (non-GAAP)	86.4	%	85.3	%	86.1	%	85.9	%

Benefit expense ratio - INSURANCE SEGMENT	3Q23		3Q22		YTD 2023		YTD 2022
GAAP	87.6	%	85.8	%	86.8	%	86.3	%
Impact of exit of employer group commercial medical products business	(0.2)	%	(0.3)	%	—	%	(0.1)	%
Adjusted (non-GAAP)	87.4	%	85.5	%	86.8	%	86.2	%

6

Operating Cost Ratio

Operating cost ratio - CONSOLIDATED	3Q23		3Q22		YTD 2023		YTD 2022
GAAP	12.5	%	13.5	%	11.8	%	13.0	%
Transaction and integration costs	—	%	—	%	—	%	(0.1)	%
Impact of exit of employer group commercial medical products business	(0.3)	%	(0.3)	%	(0.3)	%	(0.3)	%
Accrued charge related to certain anticipated litigation expenses	—	%	—	%	(0.1)	%	—	%
Value creation initiatives	(0.2)	%	(0.4)	%	(0.1)	%	(0.4)	%
Adjusted (non-GAAP)	12.0	%	12.8	%	11.3	%	12.2	%

Operating cost ratio - INSURANCE SEGMENT	3Q23		3Q22		YTD 2023		YTD 2022
GAAP	10.4	%	10.6	%	9.9	%	9.7	%
Impact of exit of employer group commercial medical products business	(0.4)	%	(0.5)	%	(0.4)	%	(0.5)	%
Accrued charge related to certain anticipated litigation expenses	(0.1)	%	—	%	(0.1)	%	—	%
Adjusted (non-GAAP)	9.9	%	10.1	%	9.4	%	9.2	%

Insurance Segment Income from Operations

Income from operations - INSURANCE SEGMENT	3Q23	3Q22	YTD 2023	YTD 2022
GAAP	$722	$873	$3,080	$2,976
Amortization associated with identifiable intangibles	6	12	17	22
Impact of exit of employer group commercial medical products business	51	70	15	48
Accrued charge related to certain anticipated litigation expenses	15	—	105	—
Adjusted (non-GAAP)	$794	$955	$3,217	$3,046

(b) Generally, when the first day of a month falls on a weekend or holiday, with the exception of January 1 (New Year's Day), the

company receives its monthly Medicare premium payment from CMS on the last business day of the previous month. On a GAAP

basis, this can result in certain quarterly cash flows from operations including more or less than three monthly payments.

Consequently, when this occurs, the company reports Adjusted cash flows from operations to reflect three payments in each quarter to match the related expenses.

Net cash from operating activities (in millions)	YTD 2023	YTD 2022
GAAP	$11,115	$9,714
Timing of premium payment from CMS	(7,073)	(5,778)
Adjusted (non-GAAP)	$4,042	$3,936

(c) The CenterWell segment Adjusted income from operations includes an adjustment to add back depreciation and amortization expense to the segment's GAAP income from operations since such an adjustment is commonly utilized for valuation purposes within the healthcare delivery industry. Prior year presentation has been recast to conform to current year presentation.

7

Income from operations - CENTERWELL SEGMENT (in millions)	3Q23	3Q22	YTD 2023	YTD 2022
GAAP	$400	$300	$1,017	$1,028
Depreciation and amortization expense	53	45	152	136
Adjusted (non-GAAP)	$453	$345	$1,169	$1,164

(d) FY 2023 projected Adjusted results exclude the following:

•FY 2023 GAAP EPS excludes the YTD 2023 impact of fair value changes of the put/call options associated with Humana's non-consolidating minority interest investments as future value changes can not be estimated.

•The fair value of publicly-traded securities, their impact on GAAP EPS, and the related non-GAAP adjustment will fluctuate depending on the public trading value of the stock. The guidance set forth herein assumes no further change in the fair value of those investments, other than the YTD 2023 adjustment.

•Transaction and integration costs, the accrual related to certain anticipated litigation expenses, and value creation initiatives reflect the respective impact of YTD 2023 activity.

Cautionary Statement

This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana’s executive officers, the words or phrases like “expects,” “believes,” “anticipates,” “intends,” “likely will result,” “estimates,” “projects” or variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the “Risk Factors” section of the company’s SEC filings, a summary of which includes but is not limited to the following:

•If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana’s profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.

•If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company’s business may be materially adversely affected. In addition, there can be no assurances that the company will be successful in maintaining or improving its Star ratings in future years.

•If Humana fails to properly maintain the integrity of its data, to strategically maintain existing or implement new information systems, to protect Humana’s proprietary rights to its systems, or to defend against cyber-security attacks or prevent other privacy or data security incidents that result in security breaches that disrupt the company's operations or in the unintentional dissemination of sensitive

8

personal information or proprietary or confidential information, the company’s business may be materially adversely affected.

•Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company’s cost of doing business.

•As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts; governmental audits and investigations; potential inadequacy of government determined payment rates; potential restrictions on profitability, including by comparison of profitability of the company’s Medicare Advantage business to non-Medicare Advantage business; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a "Fee for Service Adjuster" could have a material adverse effect on the company's operating results, financial position and cash flows.

•Humana's business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana’s results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company’s ability to expand into new markets, increasing the company’s medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company’s Medicare payment rates and increasing the company’s expenses associated with a non-deductible health insurance industry fee and other assessments); the company’s financial position (including the company’s ability to maintain the value of its goodwill); and the company’s cash flows.

•Humana’s failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company’s results of operations, financial position, and cash flows.

•If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company’s business may be adversely affected.

•Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company’s success, and its failure to do so could adversely affect the Company’s businesses, operating results and/or future performance.

•Humana’s pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.

•Changes in the prescription drug industry pricing benchmarks may adversely affect Humana’s financial performance.

•Humana’s ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.

•Downgrades in Humana’s debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

•The securities and credit markets may experience volatility and disruption, which may adversely affect Humana’s business.

•The spread of, and response to, the novel coronavirus, or COVID-19, underscores certain risks Humana faces, including those discussed above, and the ongoing, heightened uncertainty created by the pandemic precludes any prediction as to the ultimate adverse impact to Humana of COVID-19.

9

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

•Form 10-K for the year ended December 31, 2022;

•Form 10-Q for the quarters ended March 31, 2023 and June 30, 2023; and

•Form 8-Ks filed during 2023.

About Humana

Humana Inc. is committed to putting health first – for our teammates, our customers, and our company. Through our Humana insurance services, and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare, Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

10